Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography

Frontiers in Immunology(2021)10.3389/fimmu.2021.696370Source: DataRank Database

Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0.806. It has been cited 20 times, with 13 citing works in its 1-hop citation network.

N/A

0.806DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access20 citations · 13 citing works in its network

Download PDF

Cite:

Linked data & code

gen gisaid refseq doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

figshare10.6084/ m9.figshare.13490166

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.05)OA: goldTopics (78)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 57%Citation Network 43%

Base Score Contribution

0.457

From this paper's citation signal

Citation Network Contribution

0.350

From 12 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 13 citers.

Comprehensive assessment of SARS-CoV-2 antibodies against various antigenic epitopes after naive COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19)
Frontiers in Immunology20229 citations36 referencesContributes 0.064
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses
Clinical Infectious Diseases202228 citations59 referencesContributes 0.057
Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
eLife202250 citations72 referencesContributes 0.055
Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
Frontiers in Immunology20217 citations45 referencesContributes 0.046
Boosting of Cross-Reactive Antibodies to Endemic Coronaviruses by SARS-CoV-2 Infection but not Vaccination with Stabilized Spike
medRxiv202110 citations70 referencesContributes 0.034

Authors (5)

Dongmei Li ORCID,Qian Zhou ORCID,Alexander Wiltse,Martin S. Zand ORCID,Jiong Wang ORCID

Live enrichment

PubMed:34386006 PMC:PMC8353270 OpenAlex:https://openalex.org/W3184864866

National Institutes of Health

Grant: AI138500, UL1 TR002001, AI129518

NIAID NIH HHS

Grant: R01 AI129518

NCATS NIH HHS

Grant: UL1 TR002001

NIAID NIH HHS

Grant: R21 AI138500

National Institutes of Health

Grant: 5R21AI138500-02

Predictive Modeling of Multidimensional Anti-Influenza IgG Repertoires

National Institutes of Health

Grant: 5UL1TR002001-08

The University of Rochester Clinical and Translational Science Award Hub

National Institutes of Health

Grant: 5R01AI129518-02

Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity

FWCI

1.05

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.696370/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.696370/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.696370/full

journalhttps://doi.org/10.3389/fimmu.2021.696370

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34386006

Fields of Study

SARS-CoV-2 and COVID-19 ResearchBiosimilars and Bioanalytical MethodsSARS-CoV-2 detection and testing0301 basic medicine03 medical and health sciencesAntibodies, ViralBetacoronavirusCOVID-19CoronavirusCoronavirus 229E, HumanCoronavirus NL63, HumanCoronavirus Nucleocapsid ProteinsCoronavirus OC43, HumanCross ReactionsHumansImmunoassayImmunoglobulin AImmunoglobulin GImmunoglobulin MSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Spike Glycoprotein, Coronavirus

MeSH Terms

BetacoronavirusCOVID-19SARS-CoV-2Coronavirus Nucleocapsid ProteinsAntibodies, ViralCross ReactionsHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MImmunoassayCoronavirusCoronavirus 229E, HumanCoronavirus OC43, HumanSevere acute respiratory syndrome-related coronavirusCoronavirus NL63, HumanSpike Glycoprotein, Coronavirus

Keywords

AntibodyFingerstickMultiplexCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyVirologyCoronavirusMedicineBiologyInfectious disease (medical specialty)PathologyDiseaseBioinformaticsSars-cov-2Anti-S And Anti-N AntibodiesCovid-19 Vaccine StudiesCross-Reactive Antibody ImmunityHuman Coronaviruses (Hcovs)Mplex-Cov AssayPreexisting Human Coronavirus ImmunityVolumetric Absorptive Micro-Sampling (Vams)Cross ReactionsAntibodies, ViralCoronavirus OC43, HumanBetacoronavirusCoronavirus 229E, HumanCoronavirus Nucleocapsid ProteinsHumansImmunoassayCOVID-19RC581-607Immunoglobulin ACoronavirus NL63, HumanImmunoglobulin MSevere acute respiratory syndrome-related coronavirusImmunoglobulin GSpike Glycoprotein, CoronavirusImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review

10.6084/m9.figshare.20252899.v1figshare

Additional file 1 of Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review

10.6084/m9.figshare.20252899figshare